Note 12 - Segment Information - Schedule of Segment Reporting Information (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2024 |
Mar. 31, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
|
| Licensing revenue | $ 0 | $ 850 | $ 0 | $ 850 | ||
| Personnel | 16,415 | 11,174 | 29,476 | 20,695 | ||
| Research and development expense | 16,415 | 11,174 | 29,476 | 20,695 | ||
| General and administrative expense | 4,651 | 4,721 | 9,556 | 7,969 | ||
| Other income | 1,185 | 1,969 | 2,518 | 3,951 | ||
| Net loss | (19,881) | $ (16,633) | (13,076) | $ (10,787) | (36,514) | (23,863) |
| Personnel [Member] | ||||||
| Personnel | 2,417 | 1,932 | 5,187 | 3,769 | ||
| Research and development expense | 2,417 | 1,932 | 5,187 | 3,769 | ||
| General and administrative expense | 1,168 | 1,801 | 2,763 | 2,745 | ||
| General [Member] | ||||||
| Personnel | 1,709 | 1,396 | 3,358 | 3,317 | ||
| Research and development expense | 1,709 | 1,396 | 3,358 | 3,317 | ||
| General and administrative expense | 1,549 | 1,257 | 3,152 | 2,482 | ||
| Tovecimig [Member] | ||||||
| Personnel | 7,749 | 6,413 | 14,426 | 10,911 | ||
| Research and development expense | 7,749 | 6,413 | 14,426 | 10,911 | ||
| CTX-471 [Member] | ||||||
| Personnel | 1,760 | 828 | 2,459 | 1,507 | ||
| Research and development expense | 1,760 | 828 | 2,459 | 1,507 | ||
| CTX-8371 [Member] | ||||||
| Personnel | 1,044 | 605 | 1,573 | 1,191 | ||
| Research and development expense | 1,044 | 605 | 1,573 | 1,191 | ||
| CTX-10726 [Member] | ||||||
| Personnel | 1,736 | 0 | 2,473 | 0 | ||
| Research and development expense | 1,736 | 0 | 2,473 | 0 | ||
| Stock Based Compensation [Member] | ||||||
| General and administrative expense | $ 1,934 | $ 1,663 | $ 3,641 | $ 2,742 | ||
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|